⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 16, 2024

Supplementary Data from IL12/18/21 pre-activation enhances the anti-tumor efficacy of expanded γδT cells and overcomes resistance to anti-PD-L1 treatment

Huey Yee Teo Yuan Song Kylie Su Mei Yong Yonghao Liu Yu Mei Zuhairah Binte Hanafi Ying Zhu Yen Leong Chua Nicholas R. J. Gascoigne Qingfeng Chen Haiyan Liu

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Supplementary Figures and Table

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Teo et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db643587523530 https://doi.org/10.1158/2326-6066.27026510.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Data from IL12/18/21 pre-activation enhances the anti-tumor efficacy of expanded γδT cells and overcomes resistance to anti-PD-L1 treatment2024
2Data from IL12/18/21 pre-activation enhances the anti-tumor efficacy of expanded γδT cells and overcomes resistance to anti-PD-L1 treatment2024
3Supplementary Data from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy2024
4Supplementary Data from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy2024
5Supplementary Data from IL18 Receptor Signaling Regulates Tumor-Reactive CD8<sup>+</sup> T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer Model2025